Tisagenlecleucel - Novartis/University of Pennsylvania

Drug Profile

Tisagenlecleucel - Novartis/University of Pennsylvania

Alternative Names: Anti-CD19-CAR retroviral vector-transduced autologous T cells - University of Pennsylvania; Anti-CD19-CAR transduced T cells - Novartis/University of Pennsylvania; CART-019; CART-19; CART-19 cells; Chimeric antigen receptor-modified T cells against CD19 - University of Pennsylvania/Novartis; CTL 019; Kymriah; LG-740; tisagenlecleucel

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lentigen Corporation; University of Pennsylvania
  • Developer Beijing Sanwater Biological Technology; Novartis; University of Pennsylvania
  • Class CAR-T cell therapies; Cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Preregistration Diffuse large B cell lymphoma
  • Phase II Chronic lymphocytic leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
  • Preclinical Breast cancer; Mesothelioma; Ovarian cancer
  • No development reported B cell lymphoma; B cell prolymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Pancreatic cancer

Most Recent Events

  • 31 Jan 2018 Updated efficacy and adverse events data from the phase II ELIANA trial in Acute lymphoblastic leukaemia released by Children's Hospital of Philadelphia
  • 17 Jan 2018 The US FDA accepts sBLA for tisagenlecleucel for Diffuse large B-cell lymphoma (In adults, Second-line therapy or greater) for priority review
  • 17 Jan 2018 Tisagenlecleucel receives accelerated assessment status in European Union for Acute lymphoblastic leukaemia (In adolescents, In children, In adults, Second-line therapy or greater) and Diffuse large B-cell lymphoma (In adults, Second-line therapy or greater)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top